Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients

References

• Dagenais GR, St-Pierre A, Gilbert P, et al. Comparison of prognosis for men with type 2 diabetes mellitus and men with cardiovascular disease. CMAJ 2009;180(1):40-7
   PubMed Web of Science ®Google Scholar
• Karalis DG. The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes. Clin Cardiol 2008;31(6):241-8
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14(Suppl. 2):S1-113
   PubMed Web of Science ®Google Scholar
• Tovar JM, Bazaldua OV, Loffredo A. Diabetic dyslipidemia: a practical guide to therapy. J Fam Pract 2008;57(6):377-88
   PubMed Web of Science ®Google Scholar
• , Cholesterol Treatment Trialists’ (CTT) CollaboratorsKearney PM, Blackwell L et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371(9607):117-25
   PubMed Web of Science ®Google Scholar
• Fazio S. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Clin Ther 2008;30:294-306
   PubMed Web of Science ®Google Scholar
• Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidaemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-76
   PubMed Web of Science ®Google Scholar
• FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
   PubMed Web of Science ®Google Scholar
• FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97
   PubMed Web of Science ®Google Scholar
• Seth Loomba R, Arora R. Fibrates: where are we now?. Ther Adv Cardiovasc Dis 2009;3(1):91-6
   PubMedGoogle Scholar
• Saha SA, Kizhakepunnur LG, Bahekar A, et al. The role of fibrates in the prevention of cardiovascular disease – a pooled meta-analysis of long-term randomised placebo-controlled clinical trials. Am Heart J 2007;154(5):943-53
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin–fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003;19(3):155-68
   PubMed Web of Science ®Google Scholar
• Tannous M, Cheung R, Vignini A, et al. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost 1999;82:1390-4
   PubMed Web of Science ®Google Scholar
• Zambrana JL, Velasco F, Castro P, et al. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipidemic heart transplant patients. Am J Cardiol 1997;80:836-40
   PubMed Web of Science ®Google Scholar
• Cortellaro M, Cofrancesco E, Boschetti C, et al. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone in Combination Treatment. Thromb Haemost 2000;83:549-53
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191-3
   PubMed Web of Science ®Google Scholar
• Zwacka TP, Hornbach V, Torzewski J. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 2001;103:1194-7
   PubMed Web of Science ®Google Scholar
• Okopień B, Haberka M, Madej A, et al. Extralipid effects of micronized fenofibrate in dyslipidemic patients. Pharmacol Rep 2006;58:729-35
   PubMed Web of Science ®Google Scholar
• Staels B, Koenig W, Habib A, et al. Activation of human aortic smoothmuscle is inhibited by PPAR but not by PPARα activators. Nature 1998;393:790-3
   PubMed Web of Science ®Google Scholar
• Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93
   PubMed Web of Science ®Google Scholar
• Malik J, Melenovsky V, Wichterle D, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial-FAT). Cardiovasc Res 2001;52:290-8
   PubMed Web of Science ®Google Scholar
• Moghadasian MH, Mancini GB, Frohlich JJ. Pharmacotherapy of hypercholesterolaemia: statins in clinical practice. Expert Opin Pharmacother 2000;1:683-95
   PubMedGoogle Scholar
• Gervois P, Torra IP, Fruchart JC, et al. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 2000;38:3-11
   PubMed Web of Science ®Google Scholar
• Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93
   PubMed Web of Science ®Google Scholar
• Molokhia M, McKeigue P, Curcin V, et al. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991–2006. PLoS ONE 2008;3(6):e2522
   PubMed Web of Science ®Google Scholar
• Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186-91
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Screening for diabetes (position statement). Diabetes Care 2001;24(Suppl.):S21-S24
   Google Scholar
• International Lipid Information Bureau. The ILIB Lipid Handbook for Clinical Practice: Dyslipidemia and Coronary Heart Disease, 3rd edn. New York, 2003. pp. 1-242
   Google Scholar
• Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978;200:21-7
   Google Scholar
• European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30
   PubMed Web of Science ®Google Scholar
• Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972;8:260-6
   PubMed Web of Science ®Google Scholar
• Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]. J Clin Chem Clin Biochem 1978;15:121-30
   Google Scholar
• Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bergmeyer HU (ed.) Methods of Enzymatic Analysis, 2nd English edn. New York: Academic Press, 1974. pp. 18-31
   Google Scholar
• Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
   PubMed Web of Science ®Google Scholar
• Leblond L, Marcel YL. The amphipathic alpha-helical repeats of apolipoprotein A-I are responsible for binding of high density lipoproteins to HepG2 cells. J Biol Chem 1991;266:6058-67
   PubMed Web of Science ®Google Scholar
• De Loof H, Rosseneu M, Yang CY, et al. Human apolipoprotein B: analysis of internal repeats and homology with other apolipoproteins. J Lipid Res 1987;28:1455-65
   PubMed Web of Science ®Google Scholar
• Scanu AM, Scandian L. Lipoprotein (a): structure, biology and clinical relevance. Adv Intern Med 1991;36:249-70
   PubMedGoogle Scholar
• Uterman G, Weber W. Protein composition of lipoprotein(a). J Clin Invest 1987;80:458-65
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992;2:427-38
   PubMedGoogle Scholar
• Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high performance chromatography with fluorescence detection. J Chromatography 1987;422:43-52
   PubMed Web of Science ®Google Scholar
• Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1959;17:237-46
   Google Scholar
• Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45(12):2136-41
   PubMed Web of Science ®Google Scholar
• Winer BJ. Statistical Principles in Experimental Design, 2nd Edn. New York: McGraw-Hill, 1971
   Google Scholar
• Derosa G, Cicero AE, Bertone G, et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin mono-therapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 2004;26(10):1599-607
   PubMed Web of Science ®Google Scholar
• Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95(4):462-8
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Bonds DE, Lovato LC, et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99(12A):56i-67i
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102(10 Suppl.):1K-34K
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
   PubMed Web of Science ®Google Scholar
• Ali FY, Armstrong PC, Dhanji AR, et al. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 2009;29:706-11
   PubMed Web of Science ®Google Scholar
• May HT, Anderson JL, Pearson RR, et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol 2008;101:486-9
   PubMed Web of Science ®Google Scholar